about
Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicityMolecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder CancerInhibition of Girdin enhances chemosensitivity of colorectal cancer cells to oxaliplatin.Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group studyOxaliplatin: a review in the era of molecularly targeted therapyTowards biomarker-dependent individualized chemotherapy: exploring cell-specific differences in oxaliplatin-DNA adduct distribution using accelerator mass spectrometry.Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathwaysLate-stage inhibition of autophagy enhances calreticulin surface exposure.Oxaliplatin: a review of approved uses.Pharmacokinetics and tissue distribution of novel platinum containing anticancer agent BP-C1 studied in rabbits using sector field inductively coupled plasma mass spectrometry.Pharmacodynamics of Oxaliplatin-Derived Platinum Compounds During Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Emerging Aspect Supporting the Rational Design of Treatment Protocols.Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells.Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth.Bioactive fragments synergically involved in the design of new generation Pt(ii) and Pd(ii)-based anticancer compounds.Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicityA pH responsive complexation-based drug delivery system for oxaliplatinIn vitro effects of platinum compounds on renal cellular respiration in mice.Oxaliplatin neurotoxicity--no general ion channel surface-charge effect.Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines.Colorectal cancer liver metastases organoids retain characteristics of original tumor and acquire chemotherapy resistance.Can Satraplatin be hydrated before the reduction process occurs? The DFT computational study.Novel oxaliplatin derivatives with 1-(substituted benzyl)azetidine-3,3-dicarboxylate anions. Synthesis, cytotoxicity, and interaction with DNA.
P2860
Q24655188-3A55B559-32B9-471E-91CF-7BE96E3C62F1Q28552735-D4F8401B-ADD8-449F-86FA-B05F87D596DCQ33845577-053949FA-5C82-4313-8AE7-52271CAE9D19Q33964850-BDCC56FC-E972-401D-9685-24EBA04991F9Q34541434-21EBB430-BF15-4239-9892-8A9D5E275E6CQ35041359-222B75DF-088E-40DE-8F29-4F2CB57CE9F5Q36609769-B07641E9-AC6E-47D0-8710-AA3958867363Q37107220-4F913712-7075-48AE-B323-4F4B35454A81Q37697081-172C44CE-E2B3-44E3-9911-9FE0BC5C42B4Q37965616-BFAEB2C3-7A80-4E42-AF2D-29B62B5A3249Q38275908-1B90088A-1A25-46CC-B5CA-4FBCA186F39AQ38761720-8C20FC34-B588-407D-B128-850D24150898Q38799295-9BA8305A-2FFF-4893-9494-DF100A1AFF9FQ39795363-197A6877-AF0D-4295-83E1-2B33283A6DB8Q39905338-2F48DBCE-BF70-438F-884B-BEE72A4C8B84Q41612485-D2F52897-6931-42A6-8C51-550F2AC5475CQ41912667-099B306C-80FD-427D-B1A3-E95C692A0B49Q43174500-91533897-6740-4869-90A9-B9D15A1133F7Q43183942-3DC712D2-22C9-4226-8E06-BA0F7977C6A5Q47106034-810246D2-6975-4E89-A2E5-6457D93447EEQ50055632-EC98FAE6-4BFF-4280-AF25-CF93EC8B23D1Q51362514-8BE46DF1-B9D6-4F40-A3F5-3A3375DC1A78Q53636499-D2F7105D-CD66-4364-85B5-AAAF15644D39
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Pharmacokinetics of oxaliplatin in humans.
@ast
Pharmacokinetics of oxaliplatin in humans.
@en
Pharmacokinetics of oxaliplatin in humans.
@nl
type
label
Pharmacokinetics of oxaliplatin in humans.
@ast
Pharmacokinetics of oxaliplatin in humans.
@en
Pharmacokinetics of oxaliplatin in humans.
@nl
prefLabel
Pharmacokinetics of oxaliplatin in humans.
@ast
Pharmacokinetics of oxaliplatin in humans.
@en
Pharmacokinetics of oxaliplatin in humans.
@nl
P2093
P356
P1433
P1476
Pharmacokinetics of oxaliplatin in humans.
@en
P2093
P2888
P304
P356
10.1385/MO:19:4:261
P577
2002-01-01T00:00:00Z
P6179
1009997245